Top

Published in:

01-09-2018 | Original Contribution

Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats

Authors: Sugeedha Jeyapal, Uday Kumar Putcha, Venkata Surekha Mullapudi, Sudip Ghosh, Anil Sakamuri, Suryam Reddy Kona, Sai Santosh Vadakattu, Chandana Madakasira, Ahamed Ibrahim

Published in: European Journal of Nutrition | Issue 6/2018

Abstract

Purpose

Consumption of Western diet high in fat and fructose has been attributed to the recent epidemic of nonalcoholic fatty liver disease (NAFLD). However, the impact of specific fatty acids on the progression of NAFLD to nonalcoholic steatohepatitis (NASH) is poorly understood. In the present study, we investigated the chronic effects of consumption of fructose in combination with saturated fatty acids (SFA) or trans fatty acids (TFA) on the development of NAFLD.

Methods

Male Sprague–Dawley rats were randomly assigned to six isocaloric starch/high fructose (44% of calories), high fat (39% calories) diet containing either starch–peanut oil, fructose–peanut oil, fructose–palmolein, fructose–clarified butter, fructose–coconut oil or fructose–partially hydrogenated vegetable oil and fed for 24 weeks. Palmolein, clarified butter and coconut oil were used as the source of SFA whereas partially hydrogenated vegetable oil was used as the source of TFA. Peanut oil was used as the reference oil.

Results

Long-term feeding of fructose in combination with SFA or TFA induced hepatic steatosis of similar extent associated with upregulation of stearoyl CoA desaturase-1. In contrast, fructose in combination with TFA induced NASH with fibrosis as evidenced by upregulation of hepatic proinflammatory cytokine and fibrogenic gene expression, increased hepatic oxidative stress and adipocytokine imbalance. Histopathological analysis revealed the presence of NASH with fibrosis. Further, peanut oil prevented the development of NAFLD in fructose-fed rats.

Conclusion

Fructose in combination with TFA caused NASH with fibrosis by inducing oxidative stress and inflammation, whereas, fructose in combination with SFA caused simple steatosis, suggesting that the type of fatty acid is more important for the progression of NAFLD.

Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE (2013) From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10:627–636. doi:10.1038/nrgastro.2013.149 CrossRefPubMed

Bedossa P (2017) Pathology of non-alcoholic fatty liver disease. Liver Int 37:85–89. doi:10.1111/liv.13301 CrossRefPubMed

Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK et al (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141:1249–1253. doi:10.1053/j.gastro.2011.06.061 CrossRefPubMed

Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65:1038–1048. doi:10.1016/j.metabol.2015.12.012 CrossRefPubMed

Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM (2016) Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 65:1017–1025. doi:10.1016/j.metabol.2016.01.012 CrossRefPubMed

Amarapurkar D, Kamani P, Patel NP, Kumar P, Agal S et al (2007) Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 6:161–163PubMed

Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS (2009) Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 84:84–91. doi:10.1016/j.diabres.2008.11.039 CrossRefPubMed

Asrih M, Jornayvaz FR (2015) Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link? Mol Cell Endocrinol 1:55–65. doi:10.1016/j.mce.2015.02.018 CrossRef

Ibrahim A, Natrajan S, Ghafoorunissa R (2005) Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. Metabolism 54:240–246CrossRefPubMed

10.

Natarajan S, Ibrahim A, Ghafoorunissa (2005) Dietary trans fatty acids alter diaphragm phospholipid fatty acid composition, triacylglycerol content and glucose transport in rats. Br J Nutr 93:829–833. doi:10.1079/BJN20051442 CrossRefPubMed

11.

Oddy WH, Herbison CE, Jacoby P, Ambrosini GL, O’Sullivan TA et al (2013) The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol 108:778–785. doi:10.1038/ajg.2013.95 CrossRefPubMed

12.

Asrih M, Jornayvaz FR (2014) Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr 33:186–190. doi:10.1016/j.clnu.2013.11.003 CrossRefPubMed

13.

Perito ER, Rodriguez LA, Lustig RH (2013) Dietary treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 29:170–176. doi:10.1097/MOG.0b013e32835ca11d CrossRefPubMed

14.

Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH (2010) The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7:251–264. doi:10.1038/nrgastro.2010.41 CrossRefPubMed

15.

Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI et al (2007) Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 86:899–906PubMed

16.

Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K et al (2009) Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 139:2067–2071. doi:10.3945/jn.109.105858 CrossRefPubMed

17.

Sakamuri A, Pitla S, Putcha UK, Jayapal S, Pothana S et al (2016) Transient decrease in circulatory testosterone and homocysteine precedes the development of metabolic syndrome features in fructose-fed Sprague Dawley rats. J Nutr Metab 2016:7510840. doi:10.1155/2016/7510840 CrossRefPubMedPubMedCentral

18.

Oliveira LS, Santos DA, Barbosa-da-Silva S, Mandarim-de-Lacerda CA, Aguila MB (2014) The inflammatory profile and liver damage of a sucrose-rich diet in mice. J Nutr Biochem 25:193–200. doi:10.1016/j.jnutbio.2013.10.006 CrossRefPubMed

19.

Mock K, Lateef S, Benedito VA, Tou JC (2017) High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation. J Nutr Biochem 39:32–39. doi:10.1016/j.jnutbio.2016.09.010 CrossRefPubMed

20.

Romestaing C, Piquet MA, Bedu E, Rouleau V, Dautresme M et al (2007) Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr Metab (Lond) 4:4. doi:10.1186/1743-7075-4-4 CrossRef

21.

Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA et al (2006) Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 36:485–501. doi:10.1677/jme.1.01909 CrossRefPubMed

22.

Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA et al (2011) High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 57:611–624. doi:10.1097/FJC.0b013e31821b1379 CrossRefPubMed

23.

Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ et al (2013) High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58:1632–1643. doi:10.1002/hep.26594 CrossRefPubMed

24.

Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:G987–G995. doi:10.1152/ajpgi.90272.2008 CrossRefPubMedPubMedCentral

25.

Mells JE, Fu PP, Kumar P, Smith T, Karpen SJ et al (2015) Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem 26:285–292. doi:10.1016/j.jnutbio.2014.11.002 CrossRefPubMed

26.

Ichimura M, Kawase M, Masuzumi M, Sakaki M, Nagata Y et al (2015) High-fat and high-cholesterol diet rapidly induces non-alcoholic steatohepatitis with advanced fibrosis in Sprague–Dawley rats. Hepatol Res 45:458–469. doi:10.1111/hepr.12358 CrossRefPubMed

27.

Reeves PG, Nielsen FH, Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123:1939–1951CrossRefPubMed

28.

Ghafoorunissa, Reddy V, Sesikaran B (1995) Palmolein and groundnut oil have comparable effects on blood lipids and platelet aggregation in healthy Indian subjects. Lipids 30:1163–1169. doi:10.1007/BF02536619 CrossRefPubMed

29.

Huang LL, Wan JB, Wang B, He CW, Ma H et al (2013) Suppression of acute ethanol-induced hepatic steatosis by docosahexaenoic acid is associated with downregulation of stearoyl-CoA desaturase 1 and inflammatory cytokines. Prostaglandins Leukot Essent Fatty Acids 88:347–353. doi:10.1016/j.plefa.2013.02.002 CrossRefPubMed

30.

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRefPubMed

31.

Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126. doi:10.1016/S0076-6879(84)05016-3 CrossRefPubMed

32.

Flohé L, Günzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105:114–121CrossRefPubMed

33.

McCord JM, Fridovich I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244:6049–6055PubMed

34.

Anderson ME (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113:548–555. doi:10.1016/S0076-6879(85)13073-9 CrossRefPubMed

35.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMed

36.

Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917. doi:10.1139/o59-099 CrossRefPubMed

37.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real time quantitative PCR and the 2^−ΔΔCT method. Methods 25:402–408. doi:10.1006/meth.2001.1262 CrossRefPubMed

38.

Straub BK, Schirmacher P (2010) Pathology and biopsy assessment of non-alcoholic fatty liver disease. Dig Dis 28:197–202. doi:10.1159/000282086 CrossRefPubMed

39.

Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T et al (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22:437–443. doi:10.1002/dmrr.666 CrossRefPubMed

40.

Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A et al (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48:792–798. doi:10.1002/hep.22429 CrossRefPubMed

41.

Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA et al (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286–1292. doi:10.1053/jhep.2003.50229 CrossRefPubMed

42.

Kawano Y, Cohen DE (2013) Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 48:434–441. doi:10.1007/s00535-013-0758-5 CrossRefPubMedPubMedCentral

43.

Softic S, Cohen DE, Kahn CR (2016) Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci 61:1282–1293. doi:10.1007/s10620-016-4054-0 CrossRefPubMedPubMedCentral

44.

Dentin R, Girard J, Postic C (2005) Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87:81–86. doi:10.1016/j.biochi.2004.11.008 CrossRefPubMed

45.

Narce M, Bellenger J, Rialland M, Bellenger S (2012) Recent advances on stearoyl-CoA desaturase regulation in fatty liver diseases. Curr Drug Metab 13:1454–1463. doi:10.2174/138920012803762693 CrossRefPubMed

46.

Miyazaki M, Kim YC, Gray-Keller MP, Attie AD, Ntambi JM (2000) The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 275:30132–30138. doi:10.1074/jbc.M005488200 CrossRefPubMed

47.

Miyazaki M, Dobrzyn A, Man WC, Chu K, Sampath H et al (2004) Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J Biol Chem 279:25164–25171. doi:10.1074/jbc.M402781200 CrossRefPubMed

48.

Liu L, Wang S, Yao L, Li JX, Ma P et al (2016) Long-term fructose consumption prolongs hepatic stearoyl-CoA desaturase 1 activity independent of upstream regulation in rats. Biochem Biophys Res Commun 479:643–648. doi:10.1016/j.bbrc.2016.09.160 CrossRefPubMed

49.

Sellmann C, Priebs J, Landmann M, Degen C, Engstler AJ et al (2015) Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. J Nutr Biochem 26:1183–1192. doi:10.1016/j.jnutbio.2015.05.011 CrossRefPubMed

50.

Lee JS, Jun DW, Kim EK, Jeon HJ, Nam HH (2015) Histologic and metabolic derangement in high-fat, high-fructose, and combination diet animal models. Sci World J 2015:306326. doi:10.1155/2015/306326 CrossRef

51.

Pierce AA, Duwaerts CC, Soon RK, Siao K, Grenert JP et al (2016) Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury. J Nutr Biochem 29:12–20. doi:10.1016/j.jnutbio.2015.10.020 CrossRefPubMed

52.

de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, Uleryk E, Budylowski P, Schünemann H, Beyene J, Anand SS (2015) Intake of saturated and trans unsaturated fatty acids and risk of all-cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ 351:h3978. doi:10.1136/bmj.h3978 CrossRefPubMedPubMedCentral

53.

Obara N, Fukushima K, Ueno Y, Wakui Y, Kimura O et al (2010) Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol 53:326–334. doi:10.1016/j.jhep.2010.02.029 CrossRefPubMed

54.

Machado RM, Stefano JT, Oliveira CP, Mello ES, Ferreira FD et al (2010) Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr 140:1127–1132. doi:10.3945/jn.109.117937 CrossRefPubMed

55.

Hu X, Tanaka N, Guo R, Lu Y, Nakajima T et al (2017) PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis. J Nutr Biochem 39:77–85. doi:10.1016/j.jnutbio.2016.09.015 CrossRefPubMed

56.

Kondoh Y, Kawada T, Urade R (2007) Activation of caspase 3 in HepG2 cells by elaidic acid (t18:1). Biochim Biophys Acta 1771:500–505. doi:10.1016/j.bbalip.2007.01.012 CrossRefPubMed

57.

Rolo AP, Teodoro JS, Palmeira CM (2012) Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52:59–69. doi:10.1016/j.freeradbiomed.2011.10.003 CrossRefPubMed

58.

Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN et al (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103:1372–1379. doi:10.1111/j.1572-0241.2007.01774.x CrossRefPubMed

59.

Coulon S, Francque S, Colle I, Verrijken A, Blomme B et al (2012) Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 59:442–449. doi:10.1016/j.cyto.2012.05.001 CrossRefPubMed

60.

Polyzos SA, Kountouras J, Mantzoros CS (2016) Adipokines in nonalcoholic fatty liver disease. Metabolism 65:1062–1079. doi:10.1016/j.metabol.2015.11.006 CrossRefPubMed

61.

Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A et al (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498–3504. doi:10.1210/jc.2004-2240 CrossRefPubMed

62.

Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF et al (2016) Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59:30–43. doi:10.1007/s00125-015-3769-3 CrossRefPubMed

63.

Nieto N, Friedman SL, Greenwel P, Cederbaum AI (1999) CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 30:987–996. doi:10.1002/hep.510300433 CrossRefPubMed

64.

Tang Y, Zheng S, Chen A (2009) Curcumin eliminates leptin’s effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 150:3011–3020. doi:10.1210/en.2008-1601 CrossRefPubMedPubMedCentral

65.

Andrade JM, Paraíso AF, de Oliveira MV, Martins AM, Neto JF et al (2014) Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 30:915–919. doi:10.1016/j.nut.2013.11.016 CrossRefPubMed

66.

Chen S, Zhao X, Ran L, Wan J, Wang X et al (2015) Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis 47:226–232. doi:10.1016/j.dld.2014.11.015 CrossRefPubMed

67.

Ma F, Li P, Zhang Q, Yu L, Zhang L (2015) Rapid determination of trans-resveratrol in vegetable oils using magnetic hydrophilic multi-walled carbon nanotubes as adsorbents followed by liquid chromatography-tandem mass spectrometry. Food Chem 178:259–266. doi:10.1016/j.foodchem.2015.01.021 CrossRefPubMed

Title: Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats
Authors: Sugeedha Jeyapal
Uday Kumar Putcha
Venkata Surekha Mullapudi
Sudip Ghosh
Anil Sakamuri
Suryam Reddy Kona
Sai Santosh Vadakattu
Chandana Madakasira
Ahamed Ibrahim
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nutrition / Issue 6/2018
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-017-1492-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2018

Chronic treatment with prebiotics, probiotics and synbiotics attenuated cardiac dysfunction by improving cardiac mitochondrial dysfunction in male obese insulin-resistant rats

Soft drinks consumption is associated with nonalcoholic fatty liver disease independent of metabolic syndrome in Chinese population

Serum antioxidant capacity, biochemical profile and body composition of breast cancer survivors in a randomized Mediterranean dietary intervention study

Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis

Cellular zinc homeostasis modulates polarization of THP-1-derived macrophages

Reply to ZT Lopez-Ixta

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage